AKTS Aktis Oncology, Inc.
$16.45▲ +4.58%
Healthcare
Other
Volume 324.7K
Avg Volume (10D) 367.8K
Key Metrics & Fundamentals
Market Cap
$914.94M
P/E Ratio
–
Div Yield
0.00%
52W Range
14.72 - 34.19
% vs 50 MA
-21.89%
% vs 200 MA
-21.99%
RSI-14
38.4
MACD Histogram
+0.1800
Beta (1Y vs SPY)
1.64
Free Cash Flow
-$21.85M
Gross Rev
$3.38M
Gross Profit
$3.38M
EBITDA
-$28.02M
COGS
–
Operating Exp
$32.28M
Operating Income
-$28.90M
EBIT
-$28.90M
Pretax Income
-$24.14M
Net Income
-$24.14M
EPS (Diluted)
-0.44
Price & Volume History
Loading chart…
Recent News
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
GlobeNewswire · Oct 1, 2026 8:00 AM ET
Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT
MT Newswires · Sep 9, 2026 8:36 AM ET
Aktis Oncology to Present at Upcoming September Investor Conferences
GlobeNewswire · Sep 9, 2026 8:00 AM ET
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
MT Newswires · Aug 19, 2026 11:42 AM ET
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
24/7 Wall St. · Aug 19, 2026 8:10 AM ET
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target
MT Newswires · Aug 19, 2026 7:22 AM ET
Aktis: Q2 Earnings Snapshot
Associated Press · Aug 13, 2026 4:19 PM ET
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
GlobeNewswire · Aug 13, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AKTS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.